Congestive heart failure in patients treated with doxorubicin

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

1979 • 2,308 citations

Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.

1974 • 1,451 citations

Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response

1977 • 1,116 citations

Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion

1982 • 768 citations

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1997 • 628 citations

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy

1987 • 501 citations

Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury

1997 • 383 citations

Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patients

2002 • 332 citations

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

1992 • 328 citations

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.

1998 • 283 citations

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

1997 • 271 citations

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

1985 • 247 citations

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin

1998 • 239 citations

Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin

1999 • 209 citations

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.

1983 • 198 citations

Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.

1978 • 173 citations

CLINICAL AND PHARMACOLOGIC INVESTIGATION OF THE EFFECTS OF ?-TOCOPHEROL ON ADRIAMYCIN CARDIOTOXICITY

1982 • 117 citations

Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

1997 • 116 citations

Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.

1999 • 109 citations

Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).

1981 • 107 citations

Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer

1999 • 86 citations

Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.

1993 • 62 citations

Early Detection of Anthracycline-Induced Cardiotoxicity by Radionuclide Angiocardiography

1999 • 45 citations